Invitrogen™ Caplacizumab Humanized Recombinant Human Monoclonal Antibody

Human Recombinant Monoclonal Antibody

Supplier:  Invitrogen™ MA541954

Catalog No. PIMA541954

Description

Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, 6and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression.

Specifications

• Antigen: Caplacizumab Humanized
• Classification: Recombinant Monoclonal
• Conjugate: Unconjugated
• Gene Alias: ALX-0081; caplacizumab-yhdp; PMP12A2h1-linker AAA-PMP12A2h1; VWF A1 domain
• Immunogen: Human VWF A1 domain.
• Quantity: 100 μg
• Primary or Secondary: Primary
• Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
• Form: Liquid

• Applications: ELISA, SDS-Page
• Concentration: 1.6 mg/mL
• Formulation: 20mM citric acid with 6.2% sucrose, 0.01% Tween 80 and no preservative
• Host Species: Human
• Purification Method: Protein A/G
• Regulatory Status: RUO
• Target Species: Human
• Product Type: Antibody
• Target Molecule: Chemical

Safety and Handling

WARNING: Cancer - www.P65Warnings.ca.gov